Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-06-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司自愿披露关于百悦泽（泽布替尼胶囊）美国新适应症上市许可申请进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from BeiGene Ltd. regarding the progress of a supplemental New Drug Application (sNDA) for a new indication of their drug Brukinsa (Zanubrutinib) with the FDA. It details the FDA's extension of the PDUFA target review date and provides background on the clinical trials and regulatory process. The document does not contain financial statements or detailed financial data, nor is it a transcript, report, or presentation. It is a regulatory announcement about drug approval progress and associated risks. The document length is short (2518 characters) and it is clearly an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-06-13 Chinese
百济神州有限公司自愿披露关于在2022年欧洲血液学协会年会上公布血液学产品组合研究数据的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. about clinical research data presented at the 2022 European Hematology Association (EHA) annual meeting. It details clinical trial results for their hematology product portfolio, including multiple phase 2 and 3 studies. The document includes detailed clinical data, safety and efficacy results, and risk disclosures related to drug development. It is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is not a presentation or transcript but a formal announcement of clinical data results. Given the detailed clinical trial data and research results disclosed, this document fits best as a Regulatory Filings (RNS) type, which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length (5947 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure. Therefore, the classification is RNS with high confidence.
2022-06-10 Chinese
百济神州有限公司自愿披露关于国家药品监督管理局批准百泽安用于治疗复发或转移性鼻咽癌的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding the approval of its drug by the National Medical Products Administration (NMPA) for a new indication. It contains no financial statements or detailed financial data, but rather regulatory and product approval information. The document is relatively short (1839 characters) and serves as an official announcement of a regulatory event impacting the company. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about drug approval and associated risks, without financial data or detailed report content.
2022-06-10 Chinese
百济神州有限公司首次公开发行网下配售限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the listing and circulation of restricted shares following an initial public offering (IPO) of a company named 百济神州有限公司. It includes specifics about the number of shares becoming tradable, the shareholders involved, lock-up periods, regulatory approvals, and compliance with securities laws. The content focuses on the release of restricted shares to the market and the related shareholder and regulatory information. This type of document is an official announcement about the circulation of shares post-IPO, not a financial report, earnings release, or management discussion. It is not a proxy statement, AGM material, or a regulatory filing of a different nature. Therefore, the most appropriate classification is a Regulatory Filing (RNS) as it is a formal regulatory announcement about share circulation and compliance, which does not fit into more specific categories like capital changes or share issues since it concerns the unlocking and listing of restricted shares after an IPO.
2022-06-07 Chinese
中国国际金融股份有限公司、高盛高华证券有限责任公司关于百济神州有限公司首次公开发行网下配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from joint sponsors regarding the listing and circulation of restricted shares from the initial public offering (IPO) of BeiGene Ltd. It references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange rules. The content focuses on the specifics of the restricted shares, their lock-up period, shareholder commitments, and detailed shareholder lists with share quantities and percentages. There is no indication of this being a full annual or interim financial report, earnings release, or management discussion. It is not a proxy, voting result, or board change announcement. The document is a formal regulatory compliance and verification report related to the IPO share circulation, which fits best under the category of Regulatory Filings (RNS) as it is a compliance document and does not constitute a financial report or announcement of a report publication. The document length is substantial and contains detailed data, so it is not a mere announcement but a regulatory filing.
2022-06-07 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A). It details share issuance under a share award plan, share counts before and after issuance, and related compliance confirmations. The document is titled as a "翌日披露報表" which translates to "Next Day Disclosure Report" and is a regulatory disclosure of share capital changes. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement specifically about share capital changes and share repurchases. Therefore, the appropriate classification is "Share Issue/Capital Change" (SHA). The document length is 2885 characters, which is consistent with a disclosure announcement rather than a full report.
2022-06-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.